Towards a Maraviroc long-acting injectable nanoformulation


Tatham, Lee M ORCID: 0000-0001-9448-8876, Savage, Alison C ORCID: 0000-0002-5312-9946, Dwyer, Andrew, Siccardi, Marco ORCID: 0000-0002-3539-7867, Scott, Trevor, Vourvahis, Manoli, Clark, Andrew, Rannard, Steven P ORCID: 0000-0002-6946-1097 and Owen, Andrew ORCID: 0000-0002-9819-7651 (2019) Towards a Maraviroc long-acting injectable nanoformulation. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138. pp. 92-98.

[img] Text
Towards a Maraviroc Long Acting Injectable Nanoformulation .pdf - Author Accepted Manuscript
Download (454kB)

Abstract

Suboptimal adherence to antiretroviral (ARV) therapy can lead to insufficient drug exposure leading to viral rebound and increased likelihood of resistance. This has driven the development of long-acting injectable (LAI) formulations which may mitigate some of these problems. Maraviroc (MVC) is an orally dosed CCR5 antagonist approved for use in patients infected with CCR5-trophic HIV-1. MVC prevents viral entry into host cells, is readily distributed to biologically relevant tissues and has an alternative resistance profile compared to more commonly used therapies. This makes a MVC LAI formulation particularly appealing for implementation in Pre-Exposure Prophylaxis (PrEP). A 70 wt% MVC-loaded nanodispersion stabilised with polyvinyl alcohol (PVA) and sodium 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate (AOT) was prepared using emulsion-templated freeze-drying. In vitro release rate studies revealed over a 22% decrease in MVC release rate constant across a size selective membrane compared with an aqueous solution of MVC (<5% DMSO). Pharmacokinetic studies in rats were subsequently carried out following intramuscular injection of either the nanodispersion or an aqueous MVC preparation (<5% DMSO). Results demonstrated over a 3.4-fold increase in AUC<sub>0-∞</sub> (1959.71 vs 567.17 ng.h ml), over a 2.6-fold increase in MVCs terminal half-life (t½) (140.69 vs 53.23 h) and MVC concentrations present up to 10-days. These data support development of a MVC LAI formulation with potential application in HIV therapy or prevention.

Item Type: Article
Uncontrolled Keywords: Maraviroc, Long-Acting Injectable (LAI), Long-Acting Parenteral (LAP), Intramuscular, Nanodispersion, Nanomedicine, Pharmacokinetics, Pre-exposure Prophylaxis (PrEP)
Depositing User: Symplectic Admin
Date Deposited: 04 Jul 2018 14:30
Last Modified: 08 Feb 2024 17:24
DOI: 10.1016/j.ejpb.2018.04.009
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3023348
Dimensions
Altmetric
CORE (COnnecting REpositories)